3rd Quarter - Report

INDIVIOR INC for INDIVIOR INC

Firm
Client
Income
—
Expenses
$300,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

HR955/S285, Medicaid Reentry Act, HR1384/S445 Mainstreaming Addiction Treatment Act; HR2067 Medication Access and Training Expansion Act; S5000 CARA 2.0 Act, FY2022 and FY2023 Labor-HHS-Education and Commerce-Justice-Science Appropriations; HR5376 Build Back Better Act re substance use disorder and mental health treatment; HR 7666, Restoring Hope for Mental Health and Well-being Act of 2022; HR 7667, FDA User Fee Amendments of 2022; S 4348, FDASLA Act of 2022; HR 7666, Restoring Hope for Mental Health and Well-being Act of 2022; HR 7667, FDA User Fee Amendments of 2022; S 4348, FDASLA Act of 2022

LobbyistCovered position, as disclosed
FRANK J. PURCELL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA); Centers For Medicare and Medicaid Services (CMS); Office of Natl Drug Control Policy (NDCP)

Bills named: H.R. 1384 (117th), H.R. 955 (117th), H.R. 7667 (117th), H.R. 2067 (117th), H.R. 7666 (117th), H.R. 5376 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.